Slides
Page 1
Santhera Half Year Results Presentation Six months ended 30 June 2026 30 September 2026
Page 2
Santhera speakers today Catherine Isted CFO 2 Dr. Shabir Hasham CMO Orlando Oliveira CEO
Page 3
Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities issued by Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG makes no representation (either express or implied) that the information and opinions expressed in this presentation are accurate, complete or up to date. Santhera Pharmaceuticals Holding AG disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this presentation. This presentation expressly or implicitly contains certain forward-looking statements concerning Santhera Pharmaceuticals Holding AG and its business. Certain of these forward-looking statements can be identified by the use of forward-looking terminology or by discussions of strategy, plans or intentions. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Santhera Pharmaceuticals Holding AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that any of the research and/or development projects described will succeed or that any new products or indications will be brought to market. Similarly, there can be no guarantee that Santhera Pharmaceuticals Holding AG or any future product or indication will achieve any particular level of revenue. In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products, including unexpected preclinical and clinical trial results; unexpected regulatory actions or delays or government regulation generally; the Santhera Pharmaceuticals Holding AG's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Santhera Pharmaceuticals Holding AG is providing the information in this presentation as of the date of the publication and does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. 3
Page 4
HY 2026, Strong commercial momentum and expanding global access position AGAMREE® for continued growth Four of five major EU markets now commercially launched • Pricing and reimbursement agreements secured in Spain and Italy • Continued strong commercial momentum in Germany (volumes up 50% in H1 26 over H1 25) and the UK (up 40% in Q2 2026 vs Q1 2026) Strategic APAC licensing agreement signed with Nxera • Exclusive licensing agreement for Japan, South Korea, Australia and New Zealand • Deal valued at up to USD 215 Mio plus royalties, including USD 30 Mio in cash and a USD 10 Mio equity investment in Santhera 1 4 Executive and Board Changes • Orlando Oliveira appointed CEO in July 2026 • Marc Clausse joined as Chief Commercial Officer in June 2026 • Dr. Srishti Gupta elected to Santhera’s Board in May 2026 Continued progress across smaller direct European markets • Swissmedic approved AGAMREE® in Switzerland in January 2026, • Pricing and reimbursement was agreed in Luxembourg in August 2026, marking the first Benelux market to secure reimbursement 2 7 Long-term data further reinforce AGAMREE®’s differentiated profile • Data from up to eight years of AGAMREE® treatment, including baseline results from the ongoing Phase 4 GUARDIAN study presented at MDA in March 2026 • Data demonstrated comparable long-term effectiveness to standard-of- care corticosteroids, alongside clinically meaningful safety advantages 3 5 Additional data and label expansion support continued growth and positioning • CHMP adopted a positive opinion recommending extension of AGAMREE®’s EU authorization to patients from two years of age • Data from real-world experience in adult, non-ambulatory DMD patients presented at ICNMD 2026, showing stabilization or improvement in upper-limb function in this patient population 6 Distributor markets continue to expand • Expanded agreement with Biomedica in July to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan • Genesis secured marketing authorization for AGAMREE® in Serbia in September, further expanding patient access across its territories 4
Page 5
EU Market access expanding Direct and via Distributors 5 Commercialized in 4 of 5 major markets Germany, UK, Spain, Italy Plus, Austria and Luxembourg Other mid-sized countries Nordics, Belgium, Netherlands, Switzerland, Portugal, Ireland Last major EU country Focused on achieving pricing that appropriately reflects AGAMREE’s value and is consistent with established major European markets. Alternative access pathways, where available, are being evaluated Reimbursement process requires full resubmission of data Commercial launch not expected before 2028 Potential routes to accelerate access are being explored France Also available in Europe, through Genesis, in 13 countries: Greece, Cyprus, Malta, Czechia, Poland, Romania, Hungary, Bulgaria, Slovenia, Croatia, Lithuania, Serbia and Estonia
Page 6
Rapid adoption of AGAMREE® by patients and payers across launched markets Germany H1 2026 German volumes up >50% vs H1 2025 In Germany over 40% of steroid using DMD patients now treated with AGAMREE ‒ newly diagnosed patients aged 4-5 ‒ switchers aged 6-12 ‒ increasing number of older DMD patients Germany is the reference market for several other countries New mandatory government-imposed pricing discount in Germany effective from Q1 2027 will be compensated for by volume increases 6 United Kingdom Orders increased by more than 40% in Q2 2026 compared with Q1 2026 Uptake continued to progress, supported by: ‒ Increasing systematic adoption across specialist DMD centres ‒ Benefit from updated treatment guidelines ‒ Improved access initiatives, including home delivery programs Austria In Austria over 50% of steroid using DMD patients now treated with AGAMREE
Page 7
Strong momentum across distributor markets 7 Commercial momentum continued to strengthen across Santhera’s distributor markets ‒ Genesis (Central and Eastern Europe) and Megapharm (Israel) delivering strong sales growth ‒ Increasing contributions from other distribution partners In September, Genesis Pharma secured Marketing Authorization in Serbia. ‒ This represents a key interim milestone in the continued expansion of AGAMREE access beyond the EU. ‒ Genesis now provides AGAMREE through various market access pathways to 13 Central and Eastern European countries In July 2026, Santhera further expanded its distribution agreement with Biomedica to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan ‒ Extends potential access to ~2,000 additional DMD patients across Central Asia and the Caucasus
Page 8
Significant geographic expansion in ROW since mid 2025 Recent international partnership expansion across key markets: Opportunity for additional mid- to long-term revenue and profitability with limited investment ⚫ Türkiye (Gen Ilac) Aug 25 ⚫ GCC (Uniphar) Aug 25 ⚫ India (Ikris Pharma) Aug 25 ⚫ Russia (Biomedica) Oct 25 ⚫ S. Korea (Nxera) Jan 26 ⚫ Australia/NZ (Nxera) Jan 26 ⚫ Japan (Nxera) Jan 26 ⚫ Kazakhstan (Biomedica) Jul 26 ⚫ Belarus (Biomedica) Jul 26 ⚫ Georgia (Biomedica) Jul 26 ⚫ Azerbaijan (Biomedica) Jul 26 ⚫ Uzbekistan (Biomedica) Jul 26 ⚫ Brazil/LatAm (ongoing) These new geographies add to those already signed in prior years in Israel (Megapharm) and Qatar (ASTE). 8
Page 9
USD 215 Mio APAC licensing deal with Nxera (Jan 2026) Addressing unmet needs in Japan and beyond Nxera is the exclusive strategic licensing partner for AGAMREE in Japan, South Korea, Australia and New Zealand Nxera responsible for regulatory, commercial, and manufacturing activities If a registrational bridging clinical study is required, this will be paid for by Nxera Nxera’s team has solid vamorolone knowledge via former Idorsia CMC group and APAC team, both of which were acquired from Idorsia by Nxera >2,000 DMD patients in Japan 60-70% of whom are treated with steroids USD 40 Mio upfront USD 30 Mio cash and USD 10 Mio equity at CHF 14.9 (20% premium to 30-day VWAP) Up to USD 175 Mio Sales and regulatory milestone payments Tiered royalties Double-digit royalties on net sales 9
Page 10
Nxera outlines broader ambitions for AGAMREE® 10 Nxera has indicated plans to expand AGAMREE®’s regulatory footprint and indication scope in Japan H2 2027 3 Targeted filing for regulatory approval in Japan in DMD Additional rare disease indications under consideration in Japan Indication Patient population Current standard therapy Fukuyama congenital muscular dystrophy 1,000-2,000 patients, almost exclusively in Japan Symptomatic treatment only Pediatric nephrotic syndrome (SRNS/FRNS/SDNS) Incidence: 6.5 per 100,000 children Glucocorticoids Juvenile dermatomyositis (JDM) ~400 patients in Japan; incidence 1.74 per 100,000 children Glucocorticoids Potential indication expansion in Japan Outlook Beyond Japan On track to submit a Marketing Authorization Application for AGAMREE® in South Korea during 2026, following ODD and GIFT designations from the South Korean regulatory authorities
Page 11
Catalyst (now Angelini Pharma) Continuing Strong US momentum Continuing strong momentum with US partner Catalyst , now part of Angelini Pharma Catalyst reported AGAMREE® net product revenue of USD 36.7 million in Q1 2026, up from USD 22.0 Mio in Q1 2025 Angelini Pharma completed its acquisition of Catalyst on 16 July 2026 (~USD 4.1bn), expanding Angelini's rare disease presence and establishing a direct US commercial footprint In January 2026 Catalyst noted publicly that c. 90% of DMD Centers of Excellence were using AGAMREE In February 2026 Catalyst noted that it expected US sales of $140 – $150 Mio for AGAMREE in FY 2026 In June 2026 Catalyst reported Phase 1 data suggesting AGAMREE® delivers glucocorticoid and anti- inflammatory activity without significant immunosuppressive effects at approved dosing, supporting its potential evaluation across a broader range of chronic inflammatory rare diseases 11
Page 12
China progressing well following commercial launch Reaching patients in China Sperogenix continues non-reimbursed commercial rollout of AGAMREE®, following launch in September 2025 Patient numbers continue to grow, with more than 1,000 patients treated to date Product sales to Sperogenix are expected to be significantly higher in the second half of the year, following the shipment of a larger number of batches in Q3 Focus on expanding access, preparing for potential inclusion in national reimbursement frameworks, and discussing technology transfer to potentially enable local manufacturing from 2028 2023 2024 2025 2026 Q3 Q4 Q1 Q2 Q3 Q4 H1 H2 H1 H2 Filing Mar 27 Approval Dec Soft Launch 12 *National Reimbursement Drug list
Page 13
Positive Long-Term Data (inc. GUARDIAN data) Presented March 2026 13 * For DMD patients taking corticosteroids Durable efficacy, markedly improved safety vs. standard corticosteroids in DMD Study Overview Open-label, multicenter study evaluating AGAMREE® (vamorolone) in DMD patients Analysis in up to 110 patients starting treatment at four to seven years old Patients received AGAMREE for up to eight years with a median follow-up of ~five years Efficacy Comparable long-term effectiveness to classic corticosteroids, both prednisone and deflazacort. Safety & Tolerability 80% fewer patients with vertebral fractures Maintenance of normal vs classic corticosteroids where significant stunting was observed Cataracts significantly lower than deflazacort; no glaucoma observed No new safety signals identified Future Plans From late March field-based teams have been able to start to educate physicians on this new data Additional data readouts planned over the next three years "These data provide important evidence that long-term treatment with vamorolone provides durable efficacy, with a substantial reduction in the risk of spine fractures and of improvement in height, in contrast to what is observed with conventional steroids." Professor Eugenio Mercuri Professor of Paediatrics and Child Neuropsychiatry Universita Cattolica del Sacro Cuore
Page 14
Vamorolone improves long-term bone health vs standard glucocorticoids in DMD 14 Significantly lower vertebral fracture prevalence with vamorolone vs classic CS 8.1% (3/37) on vamorolone vs 41.9% with classic CS Prevalence of boys with ≥1 vertebral fracture (A) and vertebral fracture severity (B) Grading of vertebral fractures by height loss: Grade 1 [mild]: 20–25%, Grade 2 [moderate]: 25–40% Grade 3 [severe]: >40% Substantially Lower Vertebral Fracture Risk Source: Long-term impact of vamorolone on bone health compared to standard of care glucocorticoids (SoC-GC) in boys with Duchenne Muscular Dystrophy (DMD). Guglieri Michela et al. MDA conference 2026, poster 62 S
Page 15
Vamorolone maintains efficacy with improved growth vs standard glucocorticoids in DMD Time to loss of ambulation comparable vs classic CS Efficacy maintained across pooled and individual comparators Improved long-term safety without compromising efficacy Potential for higher tolerated long-term dosing vs classic CS Height trajectories/growth maintained with vamorolone Growth stunting observed with classic CS Vamorolone is the first dissociative corticosteroid to demonstrate normal growth in DMD without compromising efficacy Comparable long-term effectiveness Maintained growth without compromising motor function Source: Comparative analysis of long-term effectiveness of vamorolone vs standard of care glucocorticoid (SoC-GC) treatment in boys with DMD. McDonald Craig M. et al. MDA conference 2026, poster 23 S15
Page 16
Independent Real-World Vamorolone Use in Adult DMD Investigator-Led Chart Review — ICNMD 2026 16 * PUL assessed in the Munich cohort only (n=13): 4 improved, 4 stabilised, 5 too recent for follow-up data. Source: Erdler M, et al. Abstract PP01.56, 19th ICNMD, 7–11 July 2026. Investigator-initiated; not sponsored by Santhera. First independent description of vamorolone use in adult DMD patients in Germany and Austria 25 19/25 8 /8 Adult DMD patients (Munich & Vienna) Previously treated with a corticosteroid Evaluable patients with stable or improved upper-limb function* Study Overview Retrospective, real-world study Independent investigator-led; two centres Munich, Germany and Vienna, Austria 25 adult DMD patients; median age 23 years (range 19–34) All patients non-ambulatory, for a median of >10 years prior to starting vamorolone Presented at the International Congress on Neuromuscular Diseases (ICNMD), July 2026 Treatment history 6 patients corticosteroid-naïve, started vamorolone first-line 19 previously treated with a corticosteroid: 8 switched directly; 11 restarted after discontinuing for 2–16 years Context and limitations Highlights opportunities for further evidence generation in adult DMD populations Interpretation is limited by sample size, retrospective design, absence of a control group, and short assessment time. Congress abstract; not peer-reviewed. Outcomes and tolerability 13 patients assessed for upper-limb function in Munich cohort; 8 patients showed stable or improve upper limb funnction. 5 too early to assess No additional safety concerns reported; retrospective analysis, not designed for systematic safety assessment Treatment effect in this small cohort is consistent with overall benefit risk profile of vamorolone to date
Page 17
Operating loss narrowed significantly to CHF 6.6 Mio (H1 2025: CHF 35.4 Mio) Financial Highlights – Half year ending 30 June 2026 Royalties & milestones increased to CHF 29.1 Mio (H1 2025: CHF 6.5 Mio) • Primarily driven by USD 30 Mio (CHF 24.2 Mio) cash upfront payment received from Nxera Total revenue grew 101% to CHF 48.3 Mio (H1 2025: CHF 24.0 Mio) • Strong growth in AGAMREE sales • Income recognized from Nxera licensing agreement Global AGAMREE sales exceeded USD 175 Mio (on a four-consecutive-quarter basis in Q2 2026) • Triggering a USD 20 Mio (CHF 16.3 Mio) milestone payment, recognized in cost of sales Cash and cash equivalents increased to CHF 41.8 Mio at 30 June 2026 (31 December 2025: CHF 22.4 Mio) Product sales grew 48% to CHF 17.2 Mio (H1 2025: CHF 11.6 Mio) • Continued strong growth across launched markets Operating expenses down 8.4% to CHF 25.0 Mio (H1 2025: CHF 27.3 Mio) • Primarily due to lower development costs 1 2 3 5 6 7 17 Revenue from the supply of products and services to partners was CHF 2.1 Mio (H1 2025: CHF 5.9 Mio) • Decrease as expected, reflecting Catalyst’s transition to direct sourcing 8
Page 18
2026 financial guidance and longer-term outlook 2026 revenue guidance maintained: FY revenues of CHF 80-90 Mio • Product sales are anticipated to grow by more than 50% • Royalty income is expected to increase year-on-year. However, royalty income from Catalyst will lag underlying US sales • Milestone income is expected to exceed 2025 levels driven primarily by the USD 30 Mio upfront payment from Nxera. (Additional sales milestones may be achieved during 2026; these are not currently included in guidance) • Revenues from product supply and services are expected to decline significantly compared to 2025, following Catalyst’s transition to direct sourcing from Q1 2026 Operating expenses (excluding share-based payments): Range of CHF 50–55 Mio Cash Outlook: While cash is expected to remain broadly stable at 30 September levels through the end of the year, the movement of inventory purchases into Q1 2027, combined with a mandatory German price reduction effective from Q1 2027, is expected to result in a decline in cash during H1 2027, before the Company returns to cash generation in the second half of the year. This change in the cash profile, however, will not require the Company to seek any additional funding. Longer term outlook – updated guidance: • 2028 revenue outlook: Approximately CHF 140 Mio (EUR 150 Mio) – including direct and distributor markets, royalties from licensing partners; excluding potential milestones payments from partners • 2030 revenue outlook: Targeting CHF 250 Mio – including direct and distributor markets, royalties from licensing partners; excluding potential milestones payments from partners18
Page 19
Expected News Flow Through Q4 2026 and 2027 Pricing agreement and commercial launch in other mid-sized EU countries Distribution agreement in South America Further long-term data from the GUARDIAN study Indication expansion updates from licensing partners In-licensing of additional product(s) enhancing operational efficiency Nxera targeting Japan regulatory filing in H2 2027 19
Page 20
Self commercialization in core European countries Go direct in Europe Acquire rights to additional synergistic late-stage rare/orphan assets Acquire rights to assets Grow AGAMREE® in synergy with other products & explore potential in additional indications with partners Additional indications Leverage international partnerships for worldwide commercialization Geographical expansion 2024 - 2026 2027 - 2030 Clear strategy with four pillars of revenue generation 20
Page 21
21 APPENDIX
Page 22
SIX Swiss Exchange listed company (SANN) • Global headquarters near Basel (Switzerland) • About 110 employees; will remain <150 employees Santhera Pharmaceuticals A Fully Integrated Commercial Stage Specialty Pharma Company 22 AGAMREE® is a differentiated product in Duchenne muscular dystrophy (DMD) • A unique dissociative corticosteroid which maintains powerful anti-inflammatory properties of traditional steroids but with an improved safety profile Global rollout underway – positive market reception • Approvals by seven authorities (U.S., EU, UK, CN, HK, CH, Canada) • Own commercialization of AGAMREE in Western European countries, launched in Germany, Austria and the UK, with Italy and Spain from Q3 2026 • Launched in the U.S. by partner Angelini Pharma and in the Chinese private payor market by partner Sperogenix • Licensed to Nxera In Jan 2026 for Japan, South Korea and Australia / New Zealand No additional funding required • Cash at the 30 June 2026 was CHF 41.8 Mio
Page 23
DMD is one of the largest rare disease markets with a clearly defined patient group Around 300’000 individuals affected globally 90% of patients are diagnosed in NA/Europe 50-75% of patients are on steroid treatment Patients are treated in specialized centers HCPs are familiar with steroid usage North America 15’000 Western Europe 13’000 Central Europe 4’000 China / SE Asia 90’000 ROW 180’000 23 Japan, SK AUS, NZ 6’000
Page 24
Large global DMD market with significant growth runway Europe 17 markets 13’000 patients North America 3 markets 15’000 patients China/SE Asia 15 markets 90’000 patients (70’000 + 20’000) ROE 20 markets 4’000 patients ROW ~ 140 markets 180’000 patients * Santhera estimates Own commercialization (100% of net sales) Upfront payment Milestone payments Royalty income Partner commercialization (>60% of net sales) Japan/S. Korea/Australia/N.Z. 4 markets 6'000 patients Market size > $ 700 Mio* > $ 350 Mio* > $ 100 Mio* > $ 100 Mio* ~ € 30 Mio* > € 150 Mio* TBD 24
Page 25
Targeting 5’000 patients on AGAMREE® in Santhera European territory by 2030 25 13’000 prevalent patients and estimated age distribution 8’000 patients on standard corticosteroids 20 10 30 Age (y) Standard corticosteroids AGAMREE Introduction of AGAMREE and market share 13’000 8’000 5’000 DMD prevalence Current corticosteroid (CS) use 50-75% (~8'000) of European patients AGAMREE treatment 2030 1. https://countrymeters.info/en/Germany ; 2. https://www.dgm.org/muskelerkrankungen/muskeldystrophie-duchenne-becker; 3. Treat-NMD query (07/2023) 25
Page 26
Targeting sales of EUR 150 Mio in Santhera territory by 2030, with growth expected to continue until 2035 26 TYPICAL PATIENT Weight 33 kg Dose 5.2 mg/kg/d Bottles 1.3 per month 15 bottles per year Assumption based on patients treated, average weight, dose and price per bottle 5’000 4’000 15’000 30’000 Current patients on standard steroids 6’000 45’000 Estimated patients on AGAMREE 150m EUR Annual cost (EUR) 60’000 13’000 8’000 DMD Patients in Europe 1. https://countrymeters.info/en/Germany ; 2. https://www.dgm.org/muskelerkrankungen/muskeldystrophie-duchenne-becker; 3. Treat-NMD query (07/2023) 26
Page 27
Expanding manufacturing capacity Santhera’s additional manufacturing site now online Q4 2025: First supply ready from second CMO Ensures supply for geographical expansion Strengthens supply chain resilience and security of supply Streamlines supply chain & reduces lead times Significant cost efficiencies through a five-fold increase in production scale Local manufacturing being established across key partner territories (U.S., China, APAC) • In 2025 Catalyst Pharmaceuticals established its own drug product manufacturing capabilities to serve its territories • Sperogenix Therapeutics plans for local manufacturing from 2028 • Nxera will be responsible for commercial production of product in its territories 27
Page 28
25 PAID TO CBC AND PARTNER GROUP PAID TO SANN Above Cap Up to Cap Summary of revenue/royalty streams Direct markets (Western Europe) Distributors (Eastern Europe & other) Licensed Catalyst / Sperogenix Revenues booked to SANN 100% >60% Low-high teens % gross royalty* Booked revenue guidance 2028: EUR 150 Mio Royalty payment to originator (in COGS line) (less mid-high single digit % royalty*) (less mid-high single digit % royalty*) (less mid-high single digit % royalty*) Net direct revenues Net distributor revenues Net royalties Booked revenue guidance 2030 > EUR 150 Mio * For sales <$500 Mio, for sales >$500 Mio additional royalties are booked but also paid away to originator28
Page 29
Summary royalty stream Royalty payments retained by SANN $’s TIME Royalty payments to CBC and Partners Group Royalty payments to originator (mid-high single digit %*) Net royalty payments (mid single digits up to 11%) Total gross royalty (low-high teens %*) * For sales <$500 Mio, for sales >$500 Mio additional royalties are booked but also paid away to originator29
Page 30
Share Capital and Major Shareholders Number ‘000 Comments Listed shares outstanding 15,896 Less Treasury (638) Basic shares outstanding 15,258 Dilution Convertible bonds 657 CHF 8,900k, Remaining to convert at a strike of CHF 13.5446 Matures Sept 2028 Warrants 237 237k at strike CHF 11.10 Employee Schemes 587 Vested Total dilution 1,481 Diluted shares outstanding 16,739 30 Share Capital – as of 31 August 2026 Major shareholders >3%* • Angelini Pharma: 9.3 % * Based on listed shares outstanding
Page 31
Protection of vamorolone through patents and orphan exclusivity *https://www.uspto.gov/web/offices/pac/mpep/s2750.html; PCT: Patent Cooperation Treaty; peds: pediatric extension ** Granted patent by USPTO in July 202231 • Patent portfolio under exclusive license from ReveraGen • Granted use patents in DMD until 2029 with expected patent term extension by up to 5 years, i.e., 2034* • Granted US patent to protect vamorolone crystal form (polymorph) and suspension with expiry in July 2040** • New formulation and method of use patents either filed or in preparation which could allow protection beyond 2040 • Orphan exclusivity until late 2030 in US and late 2035 in EU (incl. pediatric extension) Vamorolone Scope Territory Year >> 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 Method of use Musc. dys. incl. DMD, IBD, COPD, MS, ... US, Europe, Japan, S.Korea, China, ... Orphan drug exclusivity Duchenne muscular dystrophy US EU Polymorphic Form Suspension & Crystal Form I US Route of synthesis #3 Improved scalable manufacturing PCT (International) Method of use Stunting growth PCT (International) Formulations Tablet, capsules, ... PCT (International) Granted Extensions (US, EU) 7 years post approval US 10 years post approval EU Granted Filed and pending Filed and pending +2 (peds) Filed and pending
Page 32
Nimble commercial setup supports markets Headquarters functions support own country teams, licensing and commercialization partners Benelux: Belgium, Netherlands & Luxembourg; Nordics: Denmark, Sweden, Norway & Finland Santhera Germany, Austria, Switzerland United Kingdom, Ireland France Italy Spain, Portugal Benelux Nordics Distribution Partners Genesis (20 European countries) Megapharm (IL), ASTE (Qatar), GEN (Turkiye) Uniphar (five GCC Countries), Ikris (India) Clinigen (International/Named Patient) License Partners Catalyst (North America) Sperogenix (Greater China/SEA) Nxera (Japan, S. Korea, Australia, New Zealand)Medical Affairs Strategic Marketing Patient Advocacy Market Access Supply Chain Finance, IT, Legal, People & Culture Regulatory Quality & PV Central Hub 32
Page 33
Executive Management Team Orlando Oliveira Chief Executive Officer Dr. Oliver P. Kronenberg Chief Legal Officer and Secretary to the Board Dr. Shabir Hasham Chief Medical Officer Marc Schrader Chief Technology Officer Catherine Isted Chief Financial Officer Marc Clausse Chief Commercial Officer 33
Page 34
We have everything in place to successfully serve the DMD market A differentiated product with worldwide rights A nimble organization with expertise A clear growth strategy A strong & growing partner network No additional funding required 34